Trel­e­gy gets FDA thumbs-up for asth­ma, be­com­ing first triple-com­bo ther­a­py in the US

One of GSK’s biggest block­busters just got a whole new in­di­ca­tion to play with.

Trel­e­gy El­lip­ta re­ceived the green light from the FDA late Wednes­day for adults with asth­ma, be­com­ing the first triple-ther­a­py com­bi­na­tion drug to treat the con­di­tion in the Unit­ed States. The med­i­cine had been ap­proved for use in chron­ic ob­struc­tive pul­monary dis­ease since 2017 and func­tions as a once-dai­ly in­hala­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.